This case highlights the potential of ALK-targeted therapy in treating rare SMARCA4-deficient tumors and suggests a potential synergistic relationship between SMARCA4 deletion and ALK rearrangement in NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.